Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 Daily cadence·50 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHost
Recent guests
Recent episodes
Jonathan Wesley Riess MD; 2026 AACR: Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer
May 6, 2026
8m 06s
Marija Balic MD PhD, AACR 2026: Whole Exome Sequencing of ctDNA Informs Post-Neoadjuvant Therapy Options for Patients with Triple Negative Early Breast Cancer
Apr 30, 2026
10m 30s
Tao Zhu MD; AACR 2026: Anti-Claudin 6 Antibody Drug Conjugate Benefits Patients with Advanced Platinum-Resistant Ovarian Cancer with Low Toxicity
Apr 28, 2026
4m 50s
Moran Amit MD PhD; AACR 2026: Oral Intralesional PD 1 Blockade Promises Less Risk of Progression to Oral Cancer than Surgery, with Preserved Quality of Life
Apr 27, 2026
10m 14s
Byoung Chul Cho MD PhD; AACR 2026: New Generation KRAS G12C Inhibitor Brings Promising Responses Even in Patients with Advanced Lung Cancers Refractory to Previous KRAS-targeted Therapy
Apr 24, 2026
7m 58s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 5/6/26 |  Jonathan Wesley Riess MD; 2026 AACR: Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer✨ | KRAS inhibitorslung cancer+3 | Jonathan Wesley Riess MD | zoldonrasibUniversity of California Davis Comprehensive Cancer Center | — | KRAS G12Dzoldonrasib+3 | — | 8m 06s | |
| 4/30/26 |  Marija Balic MD PhD, AACR 2026: Whole Exome Sequencing of ctDNA Informs Post-Neoadjuvant Therapy Options for Patients with Triple Negative Early Breast Cancer✨ | whole exome sequencingctDNA+4 | Marija Balic MD PhD | NSABP Foundation, Inc.UPMC Hillman Cancer Center+2 | San Diego, USA | whole exome sequencingctDNA+5 | — | 10m 30s | |
| 4/28/26 |  Tao Zhu MD; AACR 2026: Anti-Claudin 6 Antibody Drug Conjugate Benefits Patients with Advanced Platinum-Resistant Ovarian Cancer with Low Toxicity✨ | Ovarian CancerAntibody Drug Conjugate+4 | Tao Zhu MD | QLS5132Zhejiang Cancer Hospital+1 | — | Anti-Claudin 6Ovarian Cancer+6 | — | 4m 50s | |
| 4/27/26 |  Moran Amit MD PhD; AACR 2026: Oral Intralesional PD 1 Blockade Promises Less Risk of Progression to Oral Cancer than Surgery, with Preserved Quality of Life✨ | oral cancerintralesional PD 1 blockade+3 | Moran Amit MD PhD | University of Texas MD Anderson Cancer Center | Houston, Texas USA | oral cancerPD 1 blockade+5 | — | 10m 14s | |
| 4/24/26 |  Byoung Chul Cho MD PhD; AACR 2026: New Generation KRAS G12C Inhibitor Brings Promising Responses Even in Patients with Advanced Lung Cancers Refractory to Previous KRAS-targeted Therapy✨ | oncologylung cancer+4 | Byoung Chul Cho MD PhD | elisrasibYonsei Cancer Center+2 | Seoul, South KoreaSAN DIEGO, USA | KRAS G12Clung cancer+6 | — | 7m 58s | |
| 4/23/26 |  Elena Garralda MD PhD, AACR 2026: Molecular Glue Degrader Improves Outcomes in Heavily Pre-treated Patients with Advanced Solid Tumors✨ | molecular glue degraderadvanced solid tumors+4 | Elena Garralda MD PhD | DKY709PDR001+5 | Barcelona, SpainSan Diego, USA | molecular glue degraderadvanced solid tumors+5 | — | 8m 38s | |
| 4/16/26 |  Icro Meattini MD; 2026 EBCC: Safe to Avoid Endocrine Therapy in Older Women with Low Risk Breast Cancers: EUROPA Study Interim Findings✨ | breast cancerendocrine therapy+4 | Icro Meattini MD | University of FlorenceAzienda Ospedaliero-Universitaria Careggi+1 | Barcelona, Spain | breast cancerendocrine therapy+6 | — | 5m 16s | |
| 4/13/26 |  Amparo Garcia-Tejedor MD, PhD; 2026 EBCC: Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema✨ | axillary radiotherapybreast cancer+4 | Amparo Garcia-Tejedor MD, PhD | University of BarcelonaBellvitge University Hospital+1 | Barcelona, Spain | axillary radiotherapyaxillary lymphadenectomy+5 | — | 6m 33s | |
| 4/6/26 |  Eline Verreck BSc; 2026 EBCC: Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer✨ | breast cancerradiation therapy+3 | Eline Verreck BSc | Erasmus University Medical CentreAudio Journal of Oncology | RotterdamBarcelona | radiation boostearly breast cancer+3 | — | 7m 01s | |
| 4/3/26 |  Fleur Mauritz MD; EBCC 2026: RAPCHEM Study Shows Risk-Based Radiotherapy De-Escalation is Safe After Primary Systemic Therapy for Early Breast Cancer✨ | radiotherapybreast cancer+4 | Fleur Mauritz MD | MAASTRO Institute of Radiation Oncology and ResearchRAPCHEM Study | MaastrichtNetherlands+1 | radiotherapybreast cancer+5 | — | 6m 08s |
Showing 10 of 10
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.